Overview
Congenital enterovirus infection refers to an infection caused by enteroviruses (including Coxsackievirus group A and B, echoviruses, and other non-polio enteroviruses) that is transmitted from mother to newborn, either transplacentally during pregnancy or perinatally around the time of delivery. This condition is classified under congenital viral diseases and can range from mild illness to severe, life-threatening disease in the neonate. The infection can affect multiple organ systems in the newborn. Key clinical manifestations include sepsis-like illness with fever or hypothermia, myocarditis (inflammation of the heart muscle), meningoencephalitis (inflammation of the brain and its surrounding membranes), hepatitis with coagulopathy (liver inflammation with bleeding disorders), and pneumonitis. Neonates are particularly vulnerable because of their immature immune systems and the potential absence of protective maternal antibodies. Skin rashes, poor feeding, lethargy, and respiratory distress are also commonly observed. Severe cases, particularly those involving myocarditis or hepatic necrosis, carry a significant risk of mortality. There is no specific antiviral therapy with proven efficacy for congenital enterovirus infection. Treatment is primarily supportive, including respiratory support, cardiovascular stabilization, and management of coagulopathy. Intravenous immunoglobulin (IVIG) has been used in severe neonatal enteroviral infections, though evidence for its efficacy remains limited. Pleconaril, an antiviral agent with activity against enteroviruses, has been investigated in clinical settings but is not widely approved for routine use. Early recognition and aggressive supportive care in a neonatal intensive care setting remain the cornerstone of management. Prognosis depends on the specific enterovirus serotype involved and the organs affected, with myocarditis and hepatitis carrying the highest morbidity and mortality.
Clinical phenotype terms— hover any for plain English:
Neonatal
Begins at or shortly after birth (first 4 weeks)
FDA & Trial Timeline
4 eventsFIDAXOMICIN: FDA approved
INMAZEB®: FDA approved
treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection
Dificid: FDA approved
DIFICID® is indicated in adult and pediatric patients aged 6 months and older for the treatment of C. difficile-associated diarrhea (CDAD).
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
1 availableDificid
DIFICID� is indicated in adult and pediatric patients aged 6 months and older for the treatment of C. difficile-associated diarrhea (CDAD).
Clinical Trials
View all trials with filters →No actively recruiting trials found for Congenital enterovirus infection at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Financial Resources
1 resourcesTravel Grants
No travel grants are currently matched to Congenital enterovirus infection.
Community
No community posts yet. Be the first to share your experience with Congenital enterovirus infection.
Start the conversation →Latest news about Congenital enterovirus infection
Disease timeline:
New recruiting trial: Nomad P-KAFO Study
A new clinical trial is recruiting patients for Congenital enterovirus infection
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Congenital enterovirus infection
What is Congenital enterovirus infection?
Congenital enterovirus infection refers to an infection caused by enteroviruses (including Coxsackievirus group A and B, echoviruses, and other non-polio enteroviruses) that is transmitted from mother to newborn, either transplacentally during pregnancy or perinatally around the time of delivery. This condition is classified under congenital viral diseases and can range from mild illness to severe, life-threatening disease in the neonate. The infection can affect multiple organ systems in the newborn. Key clinical manifestations include sepsis-like illness with fever or hypothermia, myocardit
At what age does Congenital enterovirus infection typically begin?
Typical onset of Congenital enterovirus infection is neonatal. Age of onset can vary across affected individuals.
Which specialists treat Congenital enterovirus infection?
4 specialists and care centers treating Congenital enterovirus infection are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.
What treatment and support options exist for Congenital enterovirus infection?
1 patient support program are currently tracked on UniteRare for Congenital enterovirus infection. See the treatments and support programs sections for copay assistance, eligibility, and contact details.